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Abstract
Oral Lichen Planus (OLP) is an oral inflammatory condition, mediated by host immune system reaction, presenting
basal membrane damages with inflammatory lesions in the mouth and/or skin. In this study, the role of functional
polymorphisms in the MBL2 gene, encoding for Mannose-Binding Protein C (MBP-C), a member of the innate im-
mune response and an acute-phase protein able to activate the complement cascade, was investigated to assess a
possible association with OLP susceptibility in Italian patients. Two variations at the promoter region (called H/L and
X/Y) and three at the first exon (at codon 52, 54, and 57) of the MBL2 gene were analyzed in 69 OLP patients and 244
healthy controls from northeastern Italy. Considering the polymorphisms singularly, the MBL2 X allele and C/T geno-
type of the D allele (correlated with low MBP-C expression) were associated with susceptibility to develop OLP.
Moreover, when taking into account MBL2 combined genotypes, more OLP patients were deficient MBP-C produc-
ers than not deficient, who were more represented among healthy controls. MBL2 combined genotypes, responsible
for deficient MBP-C production, are associated with an increased risk of developing OLP.
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Introduction
Oral Lichen Planus (OLP) is a chronic inflammatory
disease with unknown etiology that affects the oral mucosa
(Wang and van der Waal, 2015). The current hypothesis
about OLP etiology and pathogenesis proposes that a T-cell
mediated process causes tissue lesions, increasing local
cytokines production and altering the expression of adhe-
sion molecules (De Rossi and Ciarrocca, 2014). OLP
pathogenesis involves a series of complex non-specific an-
tigens as well as specific mechanisms, and considering the
latter, it has been suggested that basal keratinocyte apop-
tosis is triggered by CD4- and CD8-activated lymphocytes
and inflammatory cytokines (Sugerman et al., 2002; Roo-
pashree et al., 2010).
OLP is characterized by damaged basal membrane ar-
eas forming colloid bodies, resulting in inflammatory erup-
tive lesions with reddish-purple spots in the mouth and/or
skin. More aggressive forms present atrophy and/or erosion
accompanied by pain and burning sensation (Mollaoglu,
2000; de Moura Castro Jacques et al., 2003; Lukac et al.,
2006). OLP affects predominantly adults over 40 years old
and occurs more in women than in men (ratio ~ 3:2) (Suger-
man et al., 2002; Arora et al., 2016; Mozaffari et al., 2016).
At present, a cure for OLP is not available and the only
treatment is for symptoms relief (De Rossi and Ciarrocca,
2014).
The Mannose-Binding Protein C (MBP-C, also
known as, Mannose-Binding Lectin MBL) is a serum
acute-phase glycoprotein produced by the liver with a key
role in innate immunity (Turner, 2003). MBP-C is able to
activate the lectin pathway of the complement cascade
through the binding of mannose residues present on the sur-
face of pathogens (Ikeda et al., 1987), via the MBP-C-
associated serine protease (MASP)-2 pathway (Thiel et al.,
1997).
MBP-C production is enhanced by inflammatory
stimuli (Arai et al., 1993), but it is also genetically deter-
mined. The MBL2 gene (10q11.2-q21) encodes the MBP-C
protein (Madsen et al., 1994), and two polymorphisms at
position -550 (called H/L, rs11003125) and -221 (called
X/Y rs7096206) located at the promoter region have been
reported to be associated with lower MBP-C serum concen-
tration (Garred et al., 1995). Three single-base substitu-
tions in the MBL2 exon-1 at codon 52 (allele D, C >T,
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rs5030737), codon 54 (allele B, G >A, rs1800450), and
codon 57 (allele C, G >A, rs1800451) have been named al-
lele O (Sumiya et al., 1991; Madsen et al., 1994), since
these polymorphisms have the same detrimental effect on
MBP-C serum concentration, impairing oligomerization
and leading to functional deficiency; the wild type allele
was named allele A (Garred et al., 1995; Wallis and Cheng,
1999). Taken together, MBL2 promoter and exon 1 poly-
morphisms combine to form six different haplotypes
(HYA, LYA, LXA, HYD, LYB, LYC) that are correlated
with different MBP-C serum concentrations (Turner, 2003;
Garred, 2008).
Considering that OLP is an immunologically medi-
ated disease, it could be possible that a low MBP-C serum
concentration, negatively influencing the host innate im-
mune response, may impact OLP pathogenesis. To date,
just one study investigated MBL2 polymorphisms in OLP
patients, without evidencing any correlation between
MBL2 A/O variants and OLP susceptibility in Brazilian pa-
tients (Barkokebas et al., 2011). Aiming to disclose the pos-
sible role of MBL2 functional genetic variants in the
susceptibility for OLP, we analyzed MBL2 promoter and
exon 1 polymorphisms in a group of OLP patients and
healthy controls from northeastern Italy.
Subjects and Methods
Patient population
A total of 69 Italian OLP patients (51 women and 18
men, median age = 65 years, range = 37-89) and 244
healthy Caucasian individuals (188 women and 56 men,
median age = 55 years, range = 39-73) were enrolled at the
Division of Oral Medicine and Pathology (Dental Clinic,
University of Trieste, Trieste, Italy). A blood sample was
collected from each patient, immediately stored at 4°C for
no more than 24 hours, and transported at the Institute for
Maternal and Child Health IRCCS “Burlo Garofolo”,
Trieste, Italy.
Patients considered with clinical suspicion of OLP
had bilateral white reticulations in either the buccal mucosa
or tongue, regardless of whether erythema and ulcers were
present. Patients with bilaterally symmetric erythema of the
gingiva with or without striations were also enrolled. Pa-
tients with unilateral lesions or lichenoid reactions, with
concomitant autoimmune disorders or undergoing im-
munomodulating pharmacological therapies were excluded
from the study. Histopathologic confirmation was obtained
for each patient after biopsy performed with local anesthe-
sia. We then considered the clinical characteristics of the
OLP patients: more than 80% were affected by typical bi-
lateral hyperkeratotic reticulated white striae in the buccal
mucosa. A third of OLP patients were affected by upper and
lower desquamative gingivitis, sometimes recorded as an
isolated feature (10%). Ulcerative OLP was less frequent,
with the highest percentage found on bilateral buccal mu-
cosa and tongue. Palate and floor of the mouth were the
most spared sites.
In females, 15.2% reported genital involvement,
21.2% cutaneous involvement, and 6.2% had involvement
of both sites. In males, 5.9% had involvement of both sites,
whereas none of the men had an isolated genital or cutane-
ous involvement.
Informed written consent was obtained from all pa-
tients and healthy controls. This work was in accordance
with the ethical standards of the 1975 Declaration of Hel-
sinki (7th revision, 2013) and the Bio-Ethical Committee of
IRCCS Burlo Garofolo approved the study (RC03/04,
L1055, protocol number 118/10).
MBL2 genotyping
Genomic DNA was extracted from peripheral whole
blood using NucliSENS® easyMAG® (BioMérieux, Marcy
l’Etoile, France) automated system for total nucleic acid
extraction. MBL2 genotyping was performed using the fol-
lowing primers: for promoter polymorphisms, forward 5’
CCA GGG CCA ACG TAG TAA GA 3’ and reverse 5’
GAG GGG TTC ATC TGT GCC TA 3’, for exon 1 poly-
morphisms, forward 5’ GGG CAT GCT CGG TAA ATA
TG 3’ and reverse 5’ TGC CCA GAG AAT GAG AGC
TGA 3’. Polymerase chain reactions (PCR) were carried
out in a Gene-Amp 9700 Thermal cycler (Applied Bio-
systems – Thermo Fisher Scientific, Foster City, Califor-
nia, U.S.A.) using PCR buffer 1x, 1 unit of Taq Gold
enzyme, 0.2 mM dNTPs, and 2 mM MgCl2. The PCR pro-
tocol was as follows: denaturation for 30 s at 95 °C; anneal-
ing for 30 s at 55 °C; extension for 30 s at 72 °C, for 40
cycles. PCR products were visualized after electrophoresis
in a 2% agarose gel to check successful DNA amplifica-
tions and the absence of non-specific reaction products.
DNA sequencing was performed using BigDye Terminator
Cycle Sequencing Ready Reaction Kit 2.0 (Applied Bio-
system) on an automated ABI Prism 3130 Genetic
Analyser, PE, using the 3130 Data Collection Software
(Applied Biosystem). Sequences were analyzed using the
4Peaks software (http://nucleobytes.com/in-
dex.php/4peaks). Allele and genotype frequencies of MBL2
gene polymorphisms were calculated by direct counting.
We also analyzed promoter and exon 1 haplotypes, as
well as combined genotypes. Using common nomencla-
ture, the first two letters indicate the promoter region vari-
ants (alleles H/L and X/Y) and the third letter indicates the
combination of the three polymorphisms in exon 1 (A/O al-
lele). The combined genotypes were classified according to
Bouwman et al. (2006) as high (HYA/HYA, HYA/LYA,
LYA/LYA, HYA/LXA, LYA/LXA), low (LXA/LXA,
HYA/O, LYA/O) and deficient (LXA/O, O/O) producers.
Statistical analysis
Fisher’s exact test was used for pairwise comparison
of alleles, genotypes, and combined genotypes frequencies
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using contingency tables as appropriate and p-values <0.05
were considered significant. All statistical analyses were
carried out using the open-source R software version 3.1.0
(R CoreTeam, 2015). Post hoc power calculations were
performed through G*Power software version 3.1.9.2 (Faul
et al., 2007).
Results
All MBL2 SNPs analyzed were in Hardy-Weinberg
(HW) equilibrium, with the exception of the C 57 G >A
polymorphism in the OLP group (Table 1). MBL2 poly-
morphisms frequency distribution in our healthy subjects
was similar to those reported by the 1000 Genomes Project
for the European Tuscan population (Table 2) (1000
Genomes Project Consortium et al., 2012).
The comparison of MBL2 allelic and genotypic fre-
quency between OLP patients and healthy controls is re-
ported in Table 1. Five common MBL2 haplotypes were
identified: HYA, LYA, LXA, HYO, LYO. They were fur-
ther arranged in combined genotypes and assembled ac-
cording to the corresponding effect on MBP-C production
(Table 1).
Taking into account the polymorphisms singularly,
the X allele was more frequent in OLP patients compared to
healthy controls (p=0.04; OR=1.58; 95%CI=0.98-2.49)
(Table 1). Moreover, C/T genotype of exon 1 D polymor-
phism was more frequent among OLP patients than the ho-
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Table 1 - MBL2 polymorphisms allele, genotype and haplotype counts (and frequency) in OLP patients (OLP) and healthy subjects (HC).
MBL2 OLP n=69 HC n=244 OLP vs. HC p-value; Odds Ratio; 95% Confidence Interval
H/L rs11003125
L 90 (0.65) 309 (0.63) Ref.
H 48 (0.35) 121 (0.27) p=0.16; OR=1.36; 95%CI=0.88-2.08
L/L 31 (0.45) 101 (0.41) Ref.
H/L 28 (0.41) 107 (0.44) p=0.66; OR=0.85; 95%CI=0.46-1.58
H/H 10 (0.14) 36 (0.15) p=1.00; OR=0.90; 95%CI=0.36-2.14
HW

2=0.45; p=0.50 2=0.76; p=0.38
X/Y rs7096206
Y 101 (0.73) 396 (0.81) Ref.
X 37 (0.27) 92 (0.19) p=0.04; OR=1.58; 95%CI=0.98-2.49
Y/Y 39 (0.57) 162 (0.66) Ref.
X/Y 23 (0.33) 72 (0.29) p=0.36; OR=1.32; 95%CI=0.70-2.47
X/X 7 (0.10) 10 (0.04) p=0.06; OR=2.89; 95%CI=0.87-9.04
HW

2=1.01; p=0.31 2=0.31; p=0.58
D rs5030737
C 124 (0.90) 456 (0.93) Ref.
T 14 (0.10) 32 (0.07) p=0.19; OR=1.61; 95%CI=0.77-3.21
C/C 55 (0.80) 228 (0.94) Ref.
C/T 14 (0.20) 16 (0.06) p=0.002; OR=3.61; 95%CI=1.53-8.43
T/T 0 (0.00) 0 (0.00)
HW

2=0.13; p=0.72 2=0.28; p=0.60
B rs1800450
G 122 (0.88) 409 (0.84) Ref.
A 16 (0.12) 79 (0.16) p=0.24; OR=0.68; 95%CI=0.36-1.23
G/G 55 (0.80) 171 (0.70) Ref.
G/A 12 (0.17) 67 (0.27) p=0.11; OR=0.56; 95%CI=0.25-1.14
A/A 2 (0.03) 6 (0.02) p=1.00; OR=1.04; 95%CI=0.10-6.01
HW

2=0.55; p=0.46 2=0.03; p=0.85
C rs1800451
G 136 (0.99) 484 (0.99) Ref.
A 2 (0.01) 14 (0.01) p=0.54; OR=0.51; 95%CI=0.05-2.26
G/G 67 (0.97) 230 (0.96) Ref.
mozygous C/C genotype, which was more frequent among
healthy controls (p=0.002; OR=3.61; 95%CI=1.53-8.43)
(Table 1). No significant difference in frequency distribu-
tion was found between OLP patients and healthy controls
for the other polymorphisms (Table 1).
When considering MBL2 combined genotype, the de-
ficient producer (DP) combined genotype was more fre-
quent among OLP patients than the high producer (HP)
one, more frequent among healthy controls (p=0.0003;
OR=4.81; 95%CI=1.89-12.39) (Table 1). Finally, when
stratifying OLP patients according to their clinical manifes-
tations, no association was found with specific MBL2 geno-
types, haplotypes, or combined genotypes.
The power analysis showed a low power for X/Y al-
leles using Fishers post hoc test (power=0.50, =0.04), a
quite high power for D allele genotypes (power=0.83,
=0.03), a high power for combined genotypes using a 2
post hoc test (power=0.99, non-centrality parameter
=47.32, critical 2=5.99) and Fisher’s post hoc test (DP
combined genotype: power=0.93, actual =0.03).
Discussion
OLP is a multifactorial disease with several genes and
environmental factors involved in its etiopathogenesis (Su-
german et al., 2002), which is not yet completely under-
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MBL2 OLP n=69 HC n=244 OLP vs. HC p-value; Odds Ratio; 95% Confidence Interval
G/A 2 (0.03) 14 (0.06) p=0.54; OR=0.49; 95%CI=0.05-2.22
A/A 0 (0.00) 0 (0.00)
HW

2=16.38; p=5.18e-05 2=0.21; p=0.64
A/O
A 105 (0.76) 379 (0.78) Ref.
O 33 (0.24) 109 (0.22) p=0.73; OR=1.09; 95%CI=0.68-1.73
A/A 40 (0.58) 148 (0.61) Ref.
A/O 25 (0.36) 83 (0.34) p=0.77; OR=1.11; 95%CI=0.60-2.03
O/O 4 (0.06) 13 (0.05) p=0.76; OR=1.14; 95%CI=0.25-3.95
HW

2=0.06; p=0.80 2=0.09; p=0.76
MBP-C producers
MBP-C High Producers 31 (0.45) 140 (0.58) Ref.
MBP-C Low Producers 24 (0.35) 91 (0.37) p=0.65; OR=1.19; 95%CI=0.62-2.24
MBP-C Deficient Producers 14 (0.20) 13 (0.05) p=0.0003; OR=4.81; 95%CI=1.89-12.39
Table 1 (cont.)
Table 2 - MBL2 allele and genotype frequencies in the present study and Tuscan population.
MBL2 HC (current
study)
TSI 1000 GPa MBL2 HC (current
study)
TSI 1000 GPa MBL2 HC (current
study)
TSI 1000 GPa




L 309 (0.63) 136 (0.63) Y 396 (0.81) 172 (0.80)
H 121 (0.27) 78 (0.36) X 92 (0.19) 42 (0.20)
L/L 101 (0.41) 43 (0.40) Y/Y 162 (0.66) 68 (0.64)
H/L 107 (0.44) 50 (0.47) X/Y 72 (0.29) 36 (0.34)
H/H 36 (0.15) 14 (0.13) X/X 10 (0.04) 3 (0.03)
D rs5030737 B rs1800450 C rs1800451
C 456 (0.93) 205 (0.96) G 409 (0.84) 182 (0.85) G 484 (0.99) 214 (1.00)
T 32 (0.07) 9 (0.04) A 79 (0.16) 32 (0.15) A 14 (0.01) 0 (0.00)
C/C 228 (0.94) 98 (0.92) G/G 171 (0.70) 79 (0.74) G/G 230 (0.96) 107 (1.00)
C/T 16 (0.06) 9 (0.08) G/A 67 (0.27) 24 (0.22) G/A 14 (0.06) 0 (0.00)
T/T 0 (0.00) 0 A/A 6 (0.02) 4 (0.04) A/A 0 (0.00) 0 (0.00)
a1000 GP = 1000 Genomes Project Consortium et al. (2012)
stood. To date, several studies analyzed the genetic variants
involved in OLP susceptibility. Most recently, the IL-17A
G197A polymorphism has been reported to be involved in
the susceptibility to OLP in Brazilian patients (Gueiros et
al., 2017). Moreover, the IFNG (874A/T) polymorphism
has also been associated with OLP in a Saudi Arabian pop-
ulation (Al-Mohaya et al., 2016). In an Egyptian popula-
tion, the presence of IL18-137 GG and IL10-592 AA
genotypes, as well as IL18-137G and IL10-592A alleles,
have been correlated with OLP (Abdel Hay et al., 2016).
Finally, VDR FokI and CYP24A1 gene polymorphisms
have been also observed to be linked to OLP in patients and
controls from Serbia (Kujundzic et al., 2016).
To our knowledge, only one study has previously in-
vestigated the role of MBL2 A/O alleles in OLP, yet with-
out finding a correlation with susceptibility to the disease
(Barkokebas et al., 2011), as in our study. When we evalu-
ated MBL2 polymorphisms singularly, the X allele and C/T
genotype of the D allele associated with low MBP-C ex-
pression (Bouwman et al., 2006), were associated with in-
creased risk of OLP development, as well as the MBL2
combined genotypes, and the fact that DP was more fre-
quent in OLP patients than HP, which is more common
among healthy controls, suggests a possible involvement of
MBL2 in susceptibility to OLP development. Barkokebas et
al. (2011) did not analyze promoter polymorphisms and
consequently haplotypes and combined genotypes, so a
comparison with our results was not possible.
The finding that individuals carrying MBL2 DP geno-
types are more susceptible to OLP leads us to hypothesize a
scenario in which low MBP-C levels are responsible for ex-
cessive cytokines (TNF-, IL-1b and IL-6) activation, im-
pacting on the basal keratinocyte apoptosis thus negatively
influencing the development of the disease (Dean et al.,
2011).
Finally, no statistically significant association has
been observed between MBL2 genotypes, haplotypes and
combined genotypes, and the clinical characteristics of
OLP patients. The lack of association might be due to the
low number of subjects with OLP after stratification for
clinical characteristics. This issue should be reconsidered
in a larger group of OLP patients, where the severity of the
disease could be categorized, allowing a more robust statis-
tical comparison between MBL2 genetic variants and the
patients’ phenotype.
In conclusion, the association between the X allele,
C/T genotype of the D allele, and MBP-C deficient produc-
ers combined genotypes, and susceptibility to develop OLP
was supported by a quite high statistical power. However,
replica studies recruiting larger cohorts of different ethnic
origins are necessary to understand the role of MBL2 ge-
netic variants in the susceptibility of OLP development,
bearing in mind that, being a multifactorial disease, other
genetic variants are cumulatively involved in OLP etio-
pathogenesis.
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